FDA Approves Simtriyo (Centanafadine) for ADHD: Looking Beyond the Core Symptoms

Simtriyo™ is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD. It is an extended-release medication that works differently from both traditional stimulant medications and previously available nonstimulant treatments by affecting three neurotransmitter systems: norepinephrine, dopamine, and serotonin.

Centanafadine modulates the reuptake of three neurotransmitters:

· Norepinephrine

· Dopamine

· Serotonin

Dopamine and norepinephrine have long been central to our understanding of ADHD. These neurotransmitter systems contribute to attention, alertness, motivation, reward processing, working memory, arousal, and the ability to engage in goal-directed behavior.

Serotonin is more commonly discussed in relation to mood and anxiety. However, serotonin also participates in impulse control, emotional processing, sleep, stress response, and cognitive functioning.

The involvement of all three systems is important because these neurotransmitters do not operate in isolation. They interact across brain networks involved in attention, mood, motivation, memory, reward, movement, stress response, and emotional regulation. Educational materials reviewing the broader ADHD experience describe overlapping contributions from norepinephrine, dopamine, and serotonin to both diagnostic and associated symptoms.

This does not mean that ADHD is caused by a simple deficiency of one or more brain chemicals. ADHD is a complex neurodevelopmental condition involving multiple interacting biological, psychological, developmental, and environmental factors.

This reinforces the need to consider the shared neurobiological pathways that can influence attention, executive functioning, emotional regulation, mood, sleep, and stress tolerance.

The formal diagnostic symptoms of ADHD are organized primarily around:

· Inattention

· Hyperactivity

· Impulsivity

These symptoms are essential for diagnosis, but they may not fully capture how ADHD affects a person’s life.

Even when distractibility or hyperactivity improves, a patient may continue to struggle with associated difficulties that contribute to significant impairment. These may include:

· Difficulty initiating tasks

· Frequently leaving tasks unfinished

· Poor time awareness or time management

· Problems planning and prioritizing

· Working-memory difficulties

· Emotional reactivity

· Irritability or low frustration tolerance

· Feeling easily overwhelmed

· Difficulty managing stress

· Sleep disruption or irregular sleep patterns

· Relationship problems

· Low self-esteem following repeated struggles at work, school, or home

The All of ADHD educational resource emphasizes that associated symptoms can worsen the impairment already created by the diagnostic symptoms of ADHD. It identifies executive dysfunction, emotional dysregulation, social difficulties, and sleep disturbance as clinically important parts of the broader patient experience.

Clinic-based research cited in the resource has estimated that emotional dysregulation may affect approximately 34% to 70% of adults with ADHD.

These concerns matter because symptom improvement and functional improvement are not always the same.

A patient may be able to concentrate during a meeting but remain unable to initiate household tasks. Another may make fewer mistakes at work but continue to experience intense irritability when plans change. Someone else may focus well during the medication’s peak effect but struggle significantly before it starts working or after it wears off.

ADHD treatment should therefore consider not only whether symptoms improve, but whether the person is functioning more consistently in real life.

a { text-decoration: none; color: #464feb; } tr th, tr td { border: 1px solid #e6e6e6; } tr th { background-color: #f5f5f5; }

Medication decisions should be individualized and may include: